BioIVT acquires CTLS a UK blood donor facility

BioIVT acquires Clinical Trials Laboratory Services (CTLS), a donor centre and laboratory based in London, UK.

BioIVT, is a provider of research models and services for drug development. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.

All CTLS employees will join BioIVT and CTLS’ London headquarters will become the primary site in Europe for donor collections.

“This acquisition increases our capabilities and improves the efficiency with which we can deliver high quality biospecimens to our clients in Europe.”

As BioIVT acquires CTLS this increases their capacity to produce fresh peripheral blood mononuclear cells and other immune cell subsets such as natural killer cells, B cells, and T cells to meet clients’ research needs. It also enables BioIVT to ship fresh blood and blood-derived products to researchers anywhere in Europe within 24 hours.

BioIVT CEO Jeff Gatz said, “We are delighted that CTLS is now part of BioIVT. This is BioIVT’s first donor centre in Europe and we are excited to be able to address our clients’ needs by offering fresh blood and blood-derived products. CTLS expands our immune cell offering, which is one of the fastest growing segments of our company. This acquisition increases our capabilities and improves the efficiency with which we can deliver high quality biospecimens to our clients in Europe.”

UK General Manager Kelly Sapsford said, “CTLS is an excellent addition to BioIVT. The companies complement each other, with CTLS employees sharing our strong work ethic, commitment to supplying the highest quality biospecimens, and unremitting desire to advance medical research across Europe.”

“European researchers will be able to rely on BioIVT to provide a consistent supply of fresh blood and blood products for their studies. They will no longer need to contend with variable availability from hospital sources,”

CTLS Laboratory Director Dr. Rukhsana Ahsan said, “We are excited to be joining BioIVT and expanding the breadth and depth of products and services that we can offer to our customers. We are looking forward to beginning this next phase of our company’s growth and development.”

BioIVT has also acquired Optivia Biotechnology and their transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.